Acknowledgement
Supported by : 가톨릭 암진화연구센터
References
- Song, J., Kim, C. J., Cho, Y. G., Kim, S. Y., Nam, S. W., Lee, S. H., Yoo, N. J., Lee, J. Y. and Park, W. S. : Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 21, 1286 (2006). https://doi.org/10.1111/j.1440-1746.2006.04445.x
- Villanueva, A., Newell, P., Chiang, D. Y., Friedman, S. L. and Llovet, J. M. : Genomics and signaling pathways in hepatocellular carcinoma. Seminars in Liver Disease. 27, 55 (2007). https://doi.org/10.1055/s-2006-960171
- Sahadevan, K., Darby, S., Leung, H. Y., Mathers, M. E., Robson, C. N. and Gnanapragasam, V. J. : Selective overexpression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J. Pathol. 213, 82 (2007). https://doi.org/10.1002/path.2205
- Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. and Forman, D. : Global cancer statistics. CA Cancer J. Clin. 61, 69 (2011). https://doi.org/10.3322/caac.20107
- Whittaker, S., Marais, R. and Zhu, A. X. : The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 29, 4989 (2010). https://doi.org/10.1038/onc.2010.236
- de La Coste, A., Romagnolo, B., Billuart, P., Renard, C. A., Buendia, M. A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A. and Perret, C. : Somatic mutations of the betacatenin gene are frequent in mouse and human hepatocellular carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 95, 8847 (1998). https://doi.org/10.1073/pnas.95.15.8847
- Pang, A., Ng, I. O., Fan, S. T. and Kwong, Y. L. : Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genetics and Cytogenetics 146, 8 (2003). https://doi.org/10.1016/S0165-4608(03)00103-1
- Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., Yamaoka, Y. and Nakamura, Y. : AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virusmediated transfer of AXIN1. Nature Genetics. 24, 245 (2000). https://doi.org/10.1038/73448
- McKeehan, W. L., Wang, F. and Kan, M. : The heparan sulfatefibroblast growth factor family: diversity of structure and function. Prog. Nucleic. Acid Res. Mol. Biol. 59, 135 (1998).
- Eswarakumar, V. P., Lax, I. and Schlessinger, J. : Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139 (2005). https://doi.org/10.1016/j.cytogfr.2005.01.001
- Hafner, C., Vogt, T. and Hartmann, A. : FGFR3 mutations in benign skin tumors. Cell Cycle. 5, 2723 (2006). https://doi.org/10.4161/cc.5.23.3509
- Qiu, W. H., Zhou, B. S., Chu, P. G., Chen, W. G., Chung, C.,Shih, J., Hwu, P., Yeh, C., Lopez, R. and Yen, Y. : Overexpression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J. Gastroenterol. 11, 5266 (2005). https://doi.org/10.3748/wjg.v11.i34.5266
- Kompier, L. C., Lurkin, I., van der Aa, M. N., van Rhijn, B. W., van der Kwast, T. H. and Zwarthoff, E. C. : FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 5, e13821 (2010). https://doi.org/10.1371/journal.pone.0013821
- Bodoor, K., Ghabkari, A., Jaradat, Z., Alkhateeb, A., Jaradat, S., Al-Ghazo, M. A., Matalka, I., Musleh, H. and Haddad, Y. : FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 34, 724 (2010). https://doi.org/10.1016/j.canep.2010.05.003
- Tomlinson, D. C., Hurst, C. D. and Knowles, M. A. : Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 26, 5889 (2007). https://doi.org/10.1038/sj.onc.1210399
- Nam, S. W., Park, J. Y., Ramasamy, A., Shevade, S., Islam, A., Long, P. M., Park, C. K., Park, S. E., Kim, S. Y., Lee, S. H., Park, W. S., Yoo, N. J., Liu, E. T., Miller, L. D. and Lee, J. Y. : Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42, 809 (2005). https://doi.org/10.1002/hep.20878
- Cao, K., Liu, W., Nakamura, H., Enomoto, H., Yamamoto, T., Saito, M., Imanishi, H., Shimomura, S., Cao, P. and Nishiguchi, S. : Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells. Hepatol Res. 39, 1108 (2009). https://doi.org/10.1111/j.1872-034X.2009.00536.x
- Onwuazor, O. N., Wen, X. Y., Wang, D. Y., Zhuang, L., Masih- Khan, E., Claudio, J., Barlogie, B., Shaughnessy, J. D., Jr. and Stewart, A. K. : Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood. 102, 772 (2003). https://doi.org/10.1182/blood-2003-04-1204
- Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P. and Radvanyi, F. : Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 23, 18 (1999).
- Rousseau, F., el Ghouzzi, V., Delezoide, A. L., Legeai-Mallet, L., Le Merrer, M., Munnich, A. and Bonaventure, J. : Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet. 5, 509 (1996). https://doi.org/10.1093/hmg/5.4.509
- Sibley, K., Cuthbert-Heavens, D. and Knowles, M. A. : Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 20, 686 (2001). https://doi.org/10.1038/sj.onc.1204110
- Tavormina, P. L., Rimoin, D. L., Cohn, D. H., Zhu, Y. Z., Shiang, R. and Wasmuth, J. J. : Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol. Genet. 4, 2175 (1995). https://doi.org/10.1093/hmg/4.11.2175
- Winterpacht, A., Hilbert, K., Stelzer, C., Schweikardt, T., Decker, H., Segerer, H., Spranger, J. and Zabel, B. : A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol. Genomics. 2, 9 (2000).
- Park, W. J., Bellus, G. A. and Jabs, E. W. : Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development. Am. J. Hum. Genet. 57, 748 (1995).
- Hafner, C., van Oers, J. M., Vogt, T., Landthaler, M., Stoehr, R., Blaszyk, H., Hofstaedter, F., Zwarthoff, E. C. and Hartmann, A. : Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 116, 2201 (2006). https://doi.org/10.1172/JCI28163
- Superti-Furga, A., Eich, G., Bucher, H. U., Wisser, J., Giedion, A., Gitzelmann, R. and Steinmann, B. : A glycine 375-tocysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur. J. Pediatr. 154, 215 (1995). https://doi.org/10.1007/BF01954274
- Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J. M., Maroteaux, P., Le Merrer, M. and Munnich, A. : Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252 (1994). https://doi.org/10.1038/371252a0
- Shiang, R., Thompson, L. M., Zhu, Y. Z., Church, D. M., Fielder, T. J., Bocian, M., Winokur, S. T. and Wasmuth, J. J. : Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 78, 335 (1994). https://doi.org/10.1016/0092-8674(94)90302-6
- Deutz-Terlouw, P. P., Losekoot, M., Aalfs, C. M., Hennekam, R. C. and Bakker, E. : Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum Mutat. Suppl 1, S62 (1998).
- Grigelioniene, G., Hagenas, L., Eklof, O., Neumeyer, L., Haereid, P. E. and Anvret, M. : A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online. Hum Mutat. 11, 333 (1998).
- Mortier, G., Nuytinck, L., Craen, M., Renard, J. P., Leroy, J. G. and de Paepe, A. : Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. J. Med. Genet. 37, 220 (2000). https://doi.org/10.1136/jmg.37.3.220
- Prinos, P., Costa, T., Sommer, A., Kilpatrick, M. W. and Tsipouras, P. : A common FGFR3 gene mutation in hypochondroplasia. Hum Mol Genet. 4, 2097 (1995). https://doi.org/10.1093/hmg/4.11.2097
- Rousseau, F., Saugier, P., Le Merrer, M., Munnich, A., Delezoide, A. L., Maroteaux, P., Bonaventure, J., Narcy, F. and Sanak, M. : Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat. Genet. 10, 11 (1995). https://doi.org/10.1038/ng0595-11